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VitaminD is an essential nutrient for bone health andmay influence the risks of respiratory illness, adverse pregnancy
outcomes, and chronic diseases of adulthood. Because many countries have a relatively low supply of foods rich in
vitaminD and inadequate exposure to natural ultraviolet B (UVB) radiation from sunlight, an important proportion
of the global population is at risk of vitaminDdeficiency.There is general agreement that theminimumserum/plasma
25-hydroxyvitamin D concentration (25(OH)D) that protects against vitamin D deficiency–related bone disease
is approximately 30 nmol/L; therefore, this threshold is suitable to define vitamin D deficiency in population
surveys. However, efforts to assess the vitamin D status of populations in low- and middle-income countries have
been hampered by limited availability of population-representative 25(OH)D data, particularly among population
subgroups most vulnerable to the skeletal and potential extraskeletal consequences of low vitamin D status, namely
exclusively breastfed infants, children, adolescents, pregnant and lactating women, and the elderly. In the absence of
25(OH)Ddata, identification of communities thatwould benefit frompublic health interventions to improve vitamin
D statusmay require proxy indicators of the population risk of vitamin D deficiency, such as the prevalence of rickets
or metrics of usual UVB exposure. If a high prevalence of vitamin D deficiency is identified (>20% prevalence of
25(OH)D < 30 nmol/L) or the risk for vitamin D deficiency is determined to be high based on proxy indicators
(e.g., prevalence of rickets >1%), food fortification and/or targeted vitamin D supplementation policies can be
implemented to reduce the burden of vitamin D deficiency–related conditions in vulnerable populations.
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Introduction
In January and March 2017, the Sackler Institute
for Nutrition Science at the New York Academy
of Sciences and the Bill & Melinda Gates Founda-
tion, in coordination with a scientific organizing
committee, convened a working group to assess the
global prevalence and disease burden of vitamin
D deficiency, and population-based strategies to
improve vitamin D status, particularly in low- and
middle-income countries (LMICs) (i.e., defined by
theWorld Bank as either low income, lower-middle
income, or upper-middle income).1 Specifically,
the working group aimed to examine definitions
of vitamin D deficiency on the basis of biomarkers
and correlations with disease or health outcomes;
potential approaches to developing estimates of
national, regional, or global prevalence of vitamin
D deficiency and related diseases; the strength of
the existing evidence related to functional conse-
quences, morbidity, and mortality associated with
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vitamin D deficiency; criteria by which vitamin
D deficiency may be characterized as either a
national public health problem in LMICs, and/or a
condition primarily affecting high-risk subgroups;
a roadmap for reducing disease burden associated
with vitamin D deficiency in LMICs; and a research
agenda to address gaps in knowledge (see Executive
summary, Box 1).
Methods
The scientific organizing committee convened a
working group by inviting members of the scien-
tific community with expertise in micronutrient
malnutrition, pediatrics, endocrinology, laboratory
assessment of vitamin D status, epidemiology, and
micronutrient supplementation and fortification
programs. The group reviewed recent research and
policy documents and engaged in two in-person
workshops aimed at examining issues of impor-
tance to policy makers and program administrators
responsible for public health actions to assess and
address vitamin D deficiency in LMICs. The group
did not undertake new systematic reviews of the
vitamin D literature but primarily drew upon
published evidence syntheses to guide its discus-
sions and to consider the application of evidence
to LMICs. The group also relied on individual
members to bring forward specific research studies
or examples of relevant programmatic experiences.
General agreement of the group developed at the
two workshops and through subsequent email
correspondence. This paper presents an overview
of the evidence reviewed, deliberations, and
conclusions of the working group.
Vitamin D physiology
Vitamin D has essential roles in the metabolism of
calciumandphosphorus and is thus critical for bone
growth and bone mineral metabolism. Vitamin D
deficiency is known to cause two metabolic bone
diseases, rickets (in children) and osteomalacia (in
adults). In addition to facilitating the absorption
of calcium, vitamin D in its active form downreg-
ulates the release of parathyroid hormone (PTH),
which at excessive levels causes bone loss and brit-
tleness and thereby contributes to the long-term
risk of osteoporosis.2 Vitamin D also functions in
the regulation of the immune system and in the
proliferation and differentiation of numerous cell
types. Over the past two decades, laboratory and
epidemiological studies have also suggested that
low vitamin D status may be associated with a
variety of health risks, including respiratory ill-
nesses (infections and asthma),3 adverse pregnancy
outcomes,4,5 and chronic diseases of adulthood,
such as osteoporosis6 and cardiovascular disease.7,8
To date, clinical trials have contributed a limited
amount of empirical evidence to support the ben-
eficial effects of vitamin D, primarily on the risk
of respiratory infections3 and some adverse preg-
nancy outcomes;9 however, there is limited evidence
thus far from randomized clinical trials to sup-
port effects on health outcomes other than bone
health.4,7,10–12
The dominant source of vitamin D in humans is
the endogenous production of vitamin D3 (chole-
calciferol) in skin following exposure to ultraviolet
B (UVB) (290–320 nm) radiation from sunlight.
Under conditions of unconstrained UVB exposure,
humans can generate adequate circulating levels of
vitaminDwithout riskof vitaminDtoxicity.13 How-
ever, cutaneous vitamin D3 synthesis is diminished
or absent at relatively high latitudes (>35°N/S, par-
ticularly during the winter) by ecological factors
that reduce UVB penetrance (e.g., UVB-absorbing
aerosols in the atmosphere and UVB path length
through the stratosphere that changes with time of
day andmonth of the year) and by individual factors
that limit cutaneous exposure to UVB, such as dark
skin pigmentation, sun avoidant lifestyles, conser-
vative clothing habits, and liberal use of sunscreen.14
Because of the widewithin- and between-individual
variations in the contribution of UVB-induced
endogenous production to systemic vitamin D sta-
tus, dietary requirements for vitamin D have been
most commonly estimated assuming limited or no
exposure to UVB. Moreover, most public health
authorities in high-income countries recommend
limiting sun exposure and liberal use of sunscreen
to minimize the risk of skin cancer.15
VitaminD ispresentnaturally inmodest amounts
in fatty fish and egg yolks, and in lower amounts
in some other foods (Table 1).16,17 Vitamin D3 is
the main form of vitamin D found naturally in
animal-source foods and oils as well as many com-
mercial supplements, whereas vitamin D2 (ergocal-
ciferol) occurs naturally in some plants and fungi,
and is less commonly used in supplements or as
a fortificant (NB: unless otherwise distinguished,
the general term vitamin D is used to refer to both
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Box 1. Executive summary
Assessment
 Serum or plasma 25-hydroxyvitamin D (25(OH)D) concentration is the most useful biomarker of
vitamin D status.
 Vitamin D deficiency is conventionally defined as 25(OH)D below 30 nmol/L.
 Natural sources of vitamin D:
◦ Dietary: Few foods, other than fatty fish, naturally contain moderately high amounts of vitamin D,
and these foods are often not readily accessible in low- and middle-income countries (LMICs).
◦ Sunlight: Endogenous synthesis of vitamin D stimulated by ultraviolet B (UVB) radiation
exposure is heavily influenced by geographic location and/or seasonality as well as social factors,
making UVB exposure an unreliable source of vitamin D.
Consequences
 Vitamin D deficiency causes bone diseases, including rickets in children and osteomalacia in adults, and
is associated with increased risk of respiratory illness and small-for-gestational age (SGA) births.
Prevalence
 There are limited population data on vitamin D status from LMICs, but the available data suggest that
vitamin D deficiency may be widespread globally, especially in regions where vitamin D fortification
programs are not in place.
Roadmap for action: To reduce the prevalence of vitamin D deficiency, at-risk countries should consider
mandatory fortification of staple foods and/or supplementation of at-risk subgroups.
Needs assessment
 Population vitamin D status should be primarily assessed through measurement of serum/plasma
25(OH)D in a representative sample of the population. If more than 20% of the population (overall, or
within identifiable subgroups) has 25(OH)D below 30 nmol/L, public health intervention should be
considered.
 In the absence of representative 25(OH)D data, countries may also use rickets surveillance to assess the
risk of vitamin D deficiency in early childhood. Public health interventions (e.g., routine vitamin D
supplementation of breastfed infants) should be considered in settings with rickets prevalence> 1%.
 Indicators of UVB exposure may be considered in the absence of other data but should include
consideration of latitude, season, and/or climate and cultural practices whereby some groups have
limited skin exposure to sunlight.
Intervention
 Food fortification: Vitamin D can be added to numerous vehicles, including dairy products, edible oils,
and flour. Vitamin D can also be cofortified with vitamin A.
 Supplementation: Vitamin D supplementation may be considered as one approach to increasing vitamin
D status in specific target groups, such as pregnant and lactating women or breastfeeding infants. It may
also be used as an interim strategy while developing a national food fortification program.
forms together throughout the report). Since very
few foods naturally contain substantial amounts of
vitamin D, commercially fortified foods (e.g., milk
and ready-to-eat breakfast cereals) may make a siz-
able contribution to themeandaily intakeof vitamin
D in countries where these products are routinely
fortified and widely consumed. However, very few
countries currentlyhavemandatoryvitaminDforti-
fication policies and practices.18 Vitamin D in food
or supplements may be quantified in either inter-
national units (IU) or micrograms (g), whereby
1 IU = 0.025 g for both vitamin D2 and D3. It
is common for dietary guidelines to specify intakes
in terms of g/day, whereas supplemental doses are
often specified in terms of IU/dose; therefore, both
units are used throughout this report.
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Table 1. Selected examples of natural (unfortified) food sources of vitamin D16
Food IU/serving g/serving Percent DV
Salmon (sockeye) cooked, 3 ounces 570 14.2 71
Swordfish, cooked, 3 ounces 566 14.1 71
Cod liver oil, 1 teaspoon 450 11.2 56
Sardines, canned in oil, drained, 1 cup 288 7.2 36
Tuna (white), canned in water, drained, 3 ounces 68 1.7 9
Egg, 1 large hard cooked (50 g) 44 1.1 5
Beef liver, cooked (pan fried), 1 slice (81 g) 40 1.0 5
Cheese, Swiss, 1 cup (diced) 25 0.7 3
IU, international units; DV, daily value, based on 800 IU/day for adults and children over 4 years.17
1 IU = 0.025 g.
Vitamin D metabolism involves sequential
hydroxylation to generate the metabolically active
metabolite. Following vitamin D3 production in
the skin, it enters the dermal capillary bed and
is nearly 100% bound to vitamin D–binding pro-
tein (DBP).14 When vitamin D2 or D3 is absorbed
from the gut, it is incorporated into chylomi-
crons and is subsequently transferred to DBP or
albumin. Vitamin D is hydroxylated in the liver
to form 25-hydroxyvitamin D (25(OH)D), the
major circulating vitamin D metabolite. Subse-
quent hydroxylation of 25(OH)D, primarily occur-
ring in the kidneys, forms 1,25-dihydroxyvitamin
D (1,25(OH)2D), which is the most metaboli-
cally active form of the vitamin. Other tissues
and cells may also produce 1,25(OH)2D for local
autocrine/paracrine effects.19 For example, during
pregnancy, the placenta expresses both the vitamin
D receptor and the vitamin D–activating enzyme,
thereby enabling local production and action of
1,25(OH)2D.20,21
The active vitamin D metabolite, 1,25(OH)2D,
promotes intestinal absorption of calcium and
phosphorus in the gut. Low intake or absorption
of calcium and/or low vitamin D status leads to a
compensatory increase in the production of PTH,
which has a twofold effect: triggering increased renal
hydroxylation of 25(OH)D to 1,25(OH)2D, thus
makingmore of the activemetabolite available; and,
increasing bone resorption, thereby mobilizing cal-
cium from the bones to maintain serum calcium
concentration in the physiological range. Individu-
als with nutritional rickets or osteomalacia typically
present with low serum 25(OH)D, higher than nor-
mal levels of alkaline phosphatase (ALP) and PTH,
and variable concentrations of 1,25(OH)2D.22,23
Vitamin D assessment and intake
Vitamin D status assessment
Serum or plasma concentration of 25(OH)D is the
best indicator of vitamin D status, owing to its long
half-life in the body (15days), relative stability, plen-
tiful concentration in the blood, and responsiveness
to recent endogenous vitamin D production and
exogenous (dietary or supplemental) vitamin
D intake [NB: the shorthand 25(OH)D is used
throughout the article to refer to either serum or
plasma concentration of 25(OH)D)].24 Conversely,
renal production of 1,25(OH)2D is tightly regulated
by serum concentrations of calcium, phosphorus,
and PTH; 1,25(OH)2D has a half-life of just a few
hours and is present in circulation at concentrations
three orders of magnitude lower than 25(OH)D.
Thus, 1,25(OH)2D is not a useful indicator
of vitamin D intake or status.25 Although the
serum/plasma 25(OH)D concentration is an indi-
cator of recent vitamin D inputs (i.e., endogenous
production plus intake), it is not a direct measure
of functional outcomes or health effects, nor is it a
biomarker of effects of vitamin D on bone health or
other target organs. This distinction is important
when considering associations between 25(OH)D
and diseases presumptively linked to vitamin D
deficiency. Furthermore, it is widely recognized
that many acute and chronic illnesses may lower
25(OH)D owing to decreased mobility and sun
exposure, decreased intake of vitamin D–fortified
foods, or as a result of chronic inflammation;
therefore, observed associations between diseases
and 25(OH)D may be due to reverse causation.
Despite these limitations, 25(OH)D remains the
most reliable biomarker of recent vitamin D
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exposure that is currently available and measurable
in many laboratories throughout the world.
Serum 25(OH)D can be measured by various
methods (e.g., liquid chromatography–mass spec-
trometry or enzyme-linked immunosorbent assay),
although the results of each of these assays can
vary across laboratories and individual technicians,
resulting in substantial between-laboratory dif-
ferences in analytical accuracy and precision. To
promote more accurate and reliable measurement
of 25(OH)D, laboratories should use an accuracy-
based quality assurance or proficiency testing
scheme (of which there are a number available, as
described herein); ideally, laboratories conducting
25(OH)D analysis for national nutrition and
health surveys should comply with international
standardization efforts, such as the Vitamin D Stan-
dardization Program (VDSP). The VDSP, operated
out of the Office of Dietary Supplements in the
United States, has supported a recent program in
Europe whereby nationally or regionally represen-
tative 25(OH)D data were standardized to enable
more accurate assessments of the prevalence of
vitamin D deficiency in European countries.26 The
Vitamin D External Quality Assessment Scheme
(DEQAS) is a proficiency testing scheme based in
the United Kingdom that provides participating
laboratories with 20 samples per year (5 per
quarter) that have reference values for 25(OH)D3
and 25(OH)D2 concentrations assigned by the U.S.
National Institutes of Standards and Technologies
(NIST) Reference Measurement Procedures.27 To
date, DEQAS has engaged approximately 1200 lab-
oratories in 54 countries. A proficiency certificate
is issued annually to those laboratories meeting the
performance targets set by the DEQAS Advisory
Panel. In the United States, the Centers for Disease
Control and Prevention (CDC) hosts the VitaminD
Standardization-Certification Program (VDSCP),
which also evaluates the accuracy and reliability of
vitamin D tests using well-established procedures,
and certifies those that have acceptable accuracy
and precision.28 In this scheme, participating
laboratories are provided with one-time sets of 40
different referencematerials for bias assessment and
calibration, as well as 40 blinded samples per year
(10 per quarter)with reference values for 25(OH)D3
and 25(OH)D2 assigned using the Reference Mea-
surement Procedures at the CDC in order to certify
analytical performance. Several of the major assay
manufacturers and key laboratories participate in
this certification program; in 2017, there were 21
certified laboratories. The CDC also supports the
College of American Pathologists’ accuracy-based
proficiency testing program for vitamin D. Labora-
toriesmay alsodirectly purchase vitaminDstandard
reference materials “Vitamin D in Human Serum”
from the NIST, which enables laboratories to vali-
date the accuracy of their test methods and is a first
step toward standardization of vitamin D testing.29
While 25(OH)D is considered the best available
biomarker of vitamin D status, other biomarkers
present in serum have been considered as potential
functional indicators of vitamin D status related to
bone health outcomes: PTH concentration; ALP;
the ratio of 24,25(OH)2D (a degradation prod-
uct of vitamin D metabolism) to 25(OH)D; “free
25(OH)D,” which is the small fraction of the
metabolite that is not bound to DBP or albu-
min; and, bioavailable 25(OH)D, which includes
the fraction bound to albumin and free 25(OH)D.24
However, little information exists regarding the use
of these functional biomarkers to screen for the
prevalence or effects of vitamin D deficiency in
population-based surveys.
Despite the inverse association between plasma
PTH and 25(OH)D, there is considerable variability
in PTH values; for example, not all children with
radiologically diagnosed rickets have PTH concen-
trations above the upper limits of the conventional
reference range.30 In a retrospective analysis of the
relationship between PTH and 25(OH)D, one study
of children and adolescents31 suggested an inflec-
tion point at a 25(OH)D concentration of 18 ng/mL
(45 nmol/L). However, other studies have not iden-
tified a consistent inflection point that would confi-
dently enable PTH to be used as amarker of vitamin
Dsufficiency.32 Theworking groupagreed that there
is too much variability in PTH to use it exclusively
for the diagnosis of rickets or vitamin D deficiency.
Additionally, prolonged storage of frozen serum or
plasma can result in decline of measured PTH con-
centrations over time, and the relative expense of
PTH assays makes this biomarker less feasible for
use in large-scale surveys.33
ALP may be a more sensitive biomarker than
PTH for population studies assessing the functional
impact of vitamin D deficiency on bone health,
as serum ALP is nearly always elevated in active
rickets. However, it is important to note that ALP
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Figure 1. Serum25-hydroxyvitaminD(25(OH)D)concentration thresholds forvitaminDdeficiency, insufficiency, andsufficiency
developed by the Institute of Medicine (IOM),38 the Scientific Advisory Committee on Nutrition (SACN),13 the European Food
Safety Authority (EFSA),53 and the Endocrine Society.54 Dashed lines are shown for 25(OH)D ranges in which the consensus group
did not make a direct statement regarding vitamin D deficiency, adequacy, or risk of harm.
can be elevated by either calcium or vitamin D
deficiency,34,35 as well as other disease processes
(e.g., liver dysfunction). The recent guidelines
released by the Global Consensus Recommendations
on Prevention and Management of Nutritional
Rickets support the use of ALP in the diagnosis
and management of nutritional rickets caused by
vitamin D and/or calcium deficiency. However,
the guidelines recommend against using ALP for
population screening.35 The present group consid-
ered the potential utility of ALP in a public health
context, but found limited published evidence to
support the use of ALP for rickets screening or
surveillance in the general population.36 Further
research is needed to guide the application of ALP
as a population screening biomarker.
Research to develop new measurement tech-
niques, establish reference ranges, and uncover
correlations between alternative vitamin D sta-
tus/functional biomarkers for health or disease end-
points is ongoing. Although 25(OH)D is considered
the best biomarker of status for use in population
surveys, it should be interpreted cautiously andwith
consideration of assay performance characteristics,
markers of systemic inflammation (as discussed
below), and other ancillary data from the same pop-
ulation (e.g., prevalence of bone disease and other
population risk factors for vitamin D deficiency).
Definition of vitamin D deficiency based on
25(OH)D cut-points
While several different 25(OH)D cutoffs have been
used to define risk for deficiency (Fig. 1), published
cutoffs are usually 30 nmol/L and most commonly
in the 25–30nmol/L range.Differences arise because
of the consultative approaches of the organizations
taskedwithdeveloping these recommendations, and
the strength and interpretation of evidence link-
ing vitamin D status to particular health outcomes
in target populations. As 25(OH)D alone does not
accurately predict health outcomes (e.g., rickets and
fracture risk), experts suggest that a single threshold
for deficiency is unlikely to be valid in all situations
and that 25(OH)D values should be interpreted in
the context of other considerations, such as eth-
nicity, genetics, inflammation, age, calcium intake,
obesity, and other factors that influence vitamin D
status. However, there are currently insufficient data
to justify the use of individualized or customized
25(OH)D cutoffs on the basis of these factors.
Genetic factors influence vitamin D metabolism
as well as calcium and phosphate metabolism.
Notably, African Americans have overall lower
25(OH)D and a higher risk of rickets than Cau-
casians, yet have higher bone mineral density, lower
incidence of osteoporosis, and relative skeletal resis-
tance to the effects of PTH.37,38 Common single
nucleotide polymorphisms in genes related to vita-
min D metabolism are known to affect 25(OH)D
and response to supplementation.39–42
Numerous clinical and dietary factors may also
influence vitamin D status. Inflammation has been
shown to slightly reduce 25(OH)D. In an analysis of
the U.S. population involving almost 9000 adults,
27% had significantly elevated C-reactive protein
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(5 mg/L) indicative of inflammation, and, after
controlling for important covariates, 25(OH)D was
3.9 nmol/L lower in the presence of inflammation.43
The effect of inflammation on 25(OH)D concentra-
tionmaybemost relevant in hospital-based settings,
wherepatientsmaybemore likely tohave inflamma-
tion, but should be considered in future studies of
populations in LMICs whomay be at risk of chronic
low-grade inflammation. Some studies have shown
increased 25(OH)D clearance in association with
clinical conditions such as hyperparathyroidism44
and low calcium intakes,45,46 yet among healthy
individuals under habitual conditions, there are no
important effects of either calcium intake47,48 or
pregnancy on 25(OH)D.49,50 Compensatory mech-
anisms to counter potential drivers of increased vita-
min D metabolism may exist (e.g., changes in DBP
concentration) and require further investigation. In
theory, thresholds for vitaminD adequacymay vary
by body composition, life stage, or even across dif-
ferent tissues.51 For example, a 25(OH)D threshold
that is deemed sufficient for a healthy adult may be
inadequate for an infant or adolescent, who is expe-
riencing periods of rapid bone growth. However, as
previously noted, existing evidence does not provide
a strong basis for setting different 25(OH)D cutoffs
to define deficiency in different life stages or on the
basis of other individual factors.
The working group acknowledged that biochem-
ical cutoffs for risk of deficiency are driven by data
related to the risks of adverse skeletal outcomes but
do not indicate clinical thresholds that define spe-
cific diseases or risks of extraskeletal health out-
comes. Although vitamin D deficiency has been
presumptively implicated in numerous diseases,
including cancer and cardiovascular disease, the
group agreed with the North American Institute of
Medicine (IOM) and UK Scientific Advisory Com-
mittee on Nutrition (SACN) conclusions in 2011
and 2016, respectively, that “musculoskeletal health
remains the only outcome for which adequate evi-
dence exists to set guidelines for establishing vitamin
D status biomarker cutoffs.”13,38
The group further noted that various authors and
expert panels have applied inconsistent terminol-
ogy in the designation of 25(OH)D cutoffs, such as
severe deficiency, moderate deficiency, subclinical
deficiency, and insufficiency, to describe the degree
of vitaminDdeficiency in relation to 25(OH)D.As a
result, thresholds for adequacy are sometimes inap-
propriately conflated with cutoffs for deficiency.52
Some publications draw a distinction between risk
of deficiency and insufficiency (Fig. 1), a term used
to refer to 25(OH)D concentrations that are below
the threshold for sufficiency but that may not be
low enough to constitute actual clinical deficiency.
However, the general agreement of the working
group was to apply a single definition of deficiency
(versus sufficiency) for application to the proposed
roadmap.
The group recognized the evidence that supports
public health measures (e.g., food fortification)
to elevate 25(OH)D to 30 nmol/L in nearly all
individuals (i.e., to reduce the percentage of the
population with 25(OH)D < 30 nmol/L). The
group’s agreement on a 30 nmol/L threshold for
deficiency was primarily influenced by the evidence
syntheses and conclusions of the IOM (United
States/Canada)38 and the SACN (UK)13 (Fig. 1).
Given typical 25(OH)D assay imprecision and
bias, there is little meaningful difference between
thresholds at 25 nmol/L (SACN) and 30 nmol/L
(IOM); however, the working group chose to
adopt the slightly more conservative threshold
of 30 nmol/L. The group acknowledged that the
European Food Safety Authority (EFSA)53 and the
Endocrine Society54 have advocated a threshold of
50 nmol/L as the lower limit of sufficiency, which
is also the 25(OH)D level that corresponds to the
recommended dietary allowance (RDA) per IOM
guidance38 (Fig. 1). However, the general agreement
of the group was that there is insufficient evidence
to target higher 25(OH)D beyond 30 nmol/L when
undertaking population-based interventions.53,55,56
In selecting the 30 nmol/L 25(OH)D cut-point to
define deficiency, the group noted the important
distinction between a target 25(OH)D for optimal
bone health in an individual and the population
mean 25(OH)D that may need to be targeted to
ensure vitamin D adequacy in the majority of
the population. For example, a population mean
25(OH)D of 70 nmol/L might be required to
ensure that 97.5%of thepopulationhas 25(OH)D>
30 nmol/L, assuming a standard deviation of
20 nmol/L and a normal distribution. Conversely,
to target a 50 nmol/L threshold, a population
intervention may need to achieve a mean 25(OH)D
of 90 nmol/L to yield 25(OH)D > 50 nmol/L
in nearly all individuals. While these are intended
only as theoretical examples, they highlight the fact
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that population standard deviations in addition
to mean values are required to model the effect of
fortification or supplementation programs and to
ensure safe 25(OH)D distributions. The working
group considered that owing to the uncertainty and
potential variation in the shape and dispersion (i.e.,
standard deviation) of a population 25(OH)D dis-
tribution, it is most practical to focus on the percent
of the population below 30 nmol/L as the standard
indicator of inadequacy of population vitamin D
status, as many studies have done,57–59 instead of
focusing on the mean concentration. Furthermore,
in the absence of data on optimal 25(OH)D
thresholds for each factor that affects vitamin
D status, there is insufficient evidence to make
context- or group-specific recommendations. Thus,
30 nmol/L is proposed as a cutoff for deficiency
to be used across all populations and population
subgroups.
Dietary guidelines on vitamin D intake
A number of organizations have recommended
different vitamin D intake levels for their respective
target populations. A detailed list of older rec-
ommendations from a broader range of countries
was recently published.51 Recommended vitamin
D intakes are generally between 5 and 20 g/day,
depending on age and physiological status (sum-
marized in Table 2). Figure 2 demonstrates the
relationship between vitamin D intake (with very
minimal cutaneous synthesis) and 25(OH)D on the
basis of an individual-participant meta-regression
of selected dose–response studies.60
In 2011, the IOM released an update on vita-
min D intake requirements and reference ranges for
vitamin D adequacy as determined by 25(OH)D
thresholds, specifically focused on the United States
and Canada.38 The RDAs set by the IOM commit-
tee were based on the average, long-term daily vita-
minD intakes required tomaintain 25(OH)D above
50 nmol/L for the majority of the adult population;
by definition, RDAs exceed the actual requirements
of 97.5% of the population.61 In 2016, the EFSA set
adequate intakes tomaintain25(OH)Dat50nmol/L
or above in 97.5% of the population, whereas the
SACN set a recommended nutrient intake (RNI) at
the average amount required to ensure 97.5% of the
population maintain 25(OH)D above 25 nmol/L.
Several other government agencies have set intake
recommendations on the basis of the 50 nmol/L
target (Table 2). Some countries rely on or adapt
recommendations from the WHO/Food and Agri-
cultural Organization (FAO) (e.g., Singapore)62 or
the IOM (e.g., Turkey),63 or take a blanket approach
that assumes sufficient vitaminD from sunlight and
offers recommendations if exposure to sunlight is
minimal (e.g., India recommends 10 g/day under
these circumstances64).
The majority of guidelines, including those from
the WHO, do not recommend higher vitamin D
dietary intake during pregnancy or lactation—
Japan and Belgium are exceptions to this norm.65,66
While some guidelines recommend higher intakes
for the elderly, EFSA and SACN do not do so on the
basis that recommended intakes assume minimal
sun exposure and therefore the requirements of
higher risk groups aremet by the recommendations.
Some academic, clinical, and special interest groups
(e.g., the International Osteoporosis Foundation
and the Endocrine Society) have released statements
and recommendations on vitamin D intakes that
advocate higher 25(OH)D cutoffs and dietary or
supplemental vitamin D intakes.54
Guidelines usually assume minimal sun expo-
sure, and thus for individuals with regular exposure
to UVB-containing sunlight, the dietary require-
ment for vitamin D may be lower. Exceptions to
this are theNordic recommendations,which suggest
a higher intake (20 g/day) if cutaneous synthesis
is restricted, and the Japanese recommendations,
which assume adequate sun exposure. Populations
in periequatorial regions can be at risk of vitamin
D deficiency because of clothing or behavior (sun
avoidance or indoor working), as discussed further
below.
The reports and recommendations reflect a wide
range of thresholds for deficiency and sufficiency,
and recommended intakes or supplementation
doses. These differences relate to variable termi-
nologies that are not always directly comparable—
differences in the interpretation of evidence linking
health outcomes to vitamin D intakes and/or
25(OH)D, the strength of that evidence, and differ-
ences in the modeled dose–response relationship.
In particular, different modeling techniques based
on aggregation of group mean 25(OH)D values
(e.g., IOM and EFSA) versus individual participant
response data (SACN) from randomized con-
trolled trials (RCTs) contribute importantly to the
variability in estimates of dietary requirements.60
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Table 2. Vitamin D intake guidelines by age group
Organization
or country
[25(OH)D]
used as
basis for
setting DRI
Assumed
sunshine
exposure
Infants (<1
year) Children Adolescents Adults
Pregnancy and
lactation Elderly Refs.
WHO/FAO,
2004;a
WHO, 2016
27 nmol/Lb Minimal 5 g/dayRNI 5 g/dayRNI 5 g/dayRNI 5 g/dayRNI 5 g/dayRNI 10 g/dayRNI
(51–65 years)
15 g/dayRNI
(65+ years)
111,225
Australia and
New
Zealand,
2006
27.5 nmol/
Lb
Minimal 5 g/dayAI 5 g/dayAI 5 g/dayAI 5 g/dayAI
(to 50 years)
10 g/dayAI
(to 70 years)
5 g/dayAI 15 g/dayAI
(>70 years)
226
North
America
(IOM),
2011
50 nmolLc Minimal 10 g/dayAI 15 g/dayRDA 15 g/dayRDA 15 g/dayRDA 15 g/dayRDA 20 g/dayRDA 38
Nordic region
(NNR),
2012d
50 nmol/Ld Some level 10 g/dayRI 10 g/dayRI 10 g/dayRI 10 g/dayRI
(to 74 years)
10 g/dayRI 20 g/dayRI
(>75 years)
227
D-A-CH
Region
(German
Nutrition
Society),
2012
50 nmol/Lb Minimal 10 g/dayAI 20 g/dayAI 20 g/dayAI 20 g/dayAI 20 g/dayAI 20 g/dayAI 228
Japan, 2013 50 nmol/Lb Adequate 2.5 g/dayAI
(0–5 months)e
5 g/dayAI (6–
11 months)
2.5–5.5 g/dayAI 5.5 g/dayAI 5.5 g/dayAI +1.5 g/dayAI
(pregnancy)
+2.5 g/dayAI
(lactation)
5.5 g/dayAI 65
UK (SACN),
2016
25 nmol/Lf Minimal 8.5–10 g/daySI 10 g/dayRNI 10 g/dayRNI 10 g/dayRNI 10 g/dayRNI 10 g/dayRNI 13
European
Union
(EFSA),
2016
50 nmol/Lg Minimal 10 g/dayAI 15 g/dayAI 15 g/dayAI 15 g/dayAI 15 g/dayAI 15 g/dayAI 53
aRecommendation for individuals not producing sufficient endogenous vitamin D.
bCutoff for deficiency.
cLevel that meets or exceeds the requirement of 97.5% of the population.
dAssumes some level of cutaneous synthesis. RNI may be higher (20 g/day) if cutaneous synthesis is restricted.
eAssumes some level of cutaneous synthesis. In the absence of adequate sun exposure, AI is 5 g/day in 0- to 5-month old infants.
fPopulation protective level: the concentration that 97.5% of individuals in the UK should achieve, or be above, in relation to
protecting musculoskeletal health.
gLevel below which there is an increased risk of adverse musculoskeletal health outcomes and pregnancy-related health outcomes.
WHO, World Health Organization; FAO, Food and Agricultural Organization; IOM, Institute of Medicine; NNR, Nordic Nutrition
Recommendations;D-A-CH,Germany,Austria andSwitzerland; SACN,ScientificAdvisoryCommittee onNutrition; EFSA,European
Food Safety Authority; AI, adequate intake; DRI, dietary reference intake; RDA, recommended dietary allowance; RNI, recommended
nutrient intake.
On the basis of disparate interpretations of what
constitutes adequate vitamin D status, it is unsur-
prising that recommended intakes are the subject of
considerable debate. Indeed, many researchers and
physicians have argued that current recommended
dietary intakes are too low to reliably raise 25(OH)D
of insufficient persons into the range of sufficiency.
The dose–response data used to calculate intake rec-
ommendations are generally derived from studies
of Caucasian adults and elderly individuals, and
include limited data from dark-skinned popula-
tions, children, and pregnant or lactating women.
Recent studies in children67 and adolescents68 have
aided in our understanding of potential variability
in the dose–response in specific age groups, and the
working group acknowledged that intake recom-
mendations may require revision to align with new
data in the future.
Safety and upper intake level
The establishment of vitamin D requirements and
target 25(OH)D concentrations must also consider
the risk of toxicity at very high intakes or extremely
elevated 25(OH)D. Vitamin D toxicity results in
hypercalcemia and/or hypercalciuria, which may
be accompanied by impaired renal function and
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Figure 2. Association between serum 25-hydroxyvitaminD (25(OH)D) concentrations (in late winter) and total vitaminD intake
(i.e., from diet plus supplemental vitamin D) in healthy persons aged 4–86 years living at northerly latitudes (between 51° N and
60° N) based on individual patient data (IPD) meta-regression analysis (n= 882 individuals). The solid and dashed lines through
the IPD data points (black circles) correspond to the lines on the basis of the two-step (adjusted for age and baseline 25(OH)D) and
one-step IPD analyses, respectively, and the corresponding 95% prediction bands are shown in gray (the lightest being the band for
the one-step IPD analysis). Reproduced with permission from Nutrients.60
increased intestinal absorption of calcium and bone
resorption.55,69
Vitamin D toxicity does not arise from endoge-
nously synthesized vitamin D in the skin but may
be an effect of prolonged intake of excessive supple-
mental doses, and in rare cases has been caused by
excessive food fortification.Case studies have shown
that 50,000–300,000 IU/day of vitamin D supple-
mentation can cause hypercalcemia within a few
weeks.70–72 Recently, there have been reports of tox-
icity in some countries attributed to increasing use
of vitamin D supplements; for example, 25(OH)D
> 250 nmol/L was found in 4% of hospital patients
in one study in India.73 Some trials have also sug-
gested that very high bolus oral doses of vitamin D
(e.g., 500,000 IU annually) may increase the risk of
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fractures, and high dosages were associated with an
increased risk of falls in the elderly.74
The IOM and EFSA recommend an upper intake
level (UL) for vitamin D of 4000 IU/day in adults
and children 9 (IOM) and 11 (SACN, EFSA)
years of age and older.13,38,53 The IOM is the only
major consensus group to have formally desig-
nated a threshold 25(OH)D above which there
were concerns of adverse effects (125 nmol/L).
The present group considered the IOM threshold
of concern at 125 nmol/L to be overly conserva-
tive (too low). A published review of vitamin D
safety concluded that 25(OH)D< 220nmol/L poses
no known risk of harm;69 furthermore, available
data indicate that some individuals attain 25(OH)D
> 125 nmol/L naturally from UVB exposure.75
There was general agreement in the group that
25(OH)D > 200 nmol/L should be avoided to
reduce the risk of hypercalcemia and other com-
plications of vitamin D toxicity, although such
complications are only likely to arise at 25(OH)D
well above this threshold.76
Consequences of vitamin D deficiency
Bone andmusculoskeletal effects are the most com-
monly studied outcomes of vitamin D deficiency,
yet an increasing number of studies have suggested
that vitamin D may influence other important
health outcomes in infants, children, and pregnant
and lactating women. In particular, emerging data
have linked vitamin D deficiency to some adverse
pregnancy outcomes, acute respiratory infections
(ARIs), and asthma.
Rickets and bone health in children
Nutritional rickets has re-emerged as a disease
of public health importance in both high- and
low-income countries. To address this increasingly
recognized condition, the Global Consensus Rec-
ommendations on Prevention and Management of
Nutritional Rickets were published in 2016.35 This
multidisciplinary group of experts conducted a
systematic review of the literature and provided
46 evidence-based guideline recommendations.
The guidelines were primarily targeted toward
clinicians who care for children with rickets and to
health policy makers who implement public health
recommendations. Much of the evidence discussed
below was included in the formulation of the 2016
Figure 3. Radiographs of a normal knee (left) and a knee with
nutritional rickets (right). The arrows indicate the regions with
the widening of the growth plate and the frayed margins.
rickets guidelines, which directly informed the
discussion and conclusions of the present group.
At a cellular andmetabolic level, nutritional rick-
ets is a disorder of defective chondrocyte differenti-
ation andmineralization of the growth plate caused
by low vitamin D status or inadequate calcium
intake in children. A clinical diagnosis of nutritional
rickets is suspected on the basis of history and phys-
ical examination, supported by biochemical testing
and confirmed radiographically. The clinical mor-
bidity associated with nutritional rickets includes
impaired linear growth, chest wall deformity pre-
disposing to pneumonia, fractures, bone pain, leg
deformities with resultant disability, developmen-
tal delay of gross motor skills, and potentially lethal
outcomes like hypocalcemic seizures, cardiomyopa-
thy, and cardiac arrest.77–81 Biochemical features
of nutritional rickets include an elevated ALP, low
serum phosphorus and calcium, and elevated PTH.
Of these biomarkers, elevated ALP is the most sen-
sitive biochemical feature, and in its absence, active
rickets is unlikely.36,82
Radiographs of thewrists or knees are obtained to
confirm the diagnosis of active rickets. Radiography
is oftenmorewidely available than reliable biochem-
ical testing in some low-resource settings, and radio-
graphs are sufficient to make a diagnosis of rickets
(Fig. 3). A 10-point radiographic severity score is
useful for assessing the severity of rickets,83 and it
can be used to objectively measure improvement or
response to treatment and to compare the severity of
rickets between subjects. The radiographic severity
score has been widely utilized and validated in mul-
tiple populations for the diagnosis of rickets.84–86
Nutritional rickets can result from inadequate
vitamin D (reflected by low 25(OH)D), very low
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dietary calcium intake, or a combination of both
vitamin D and calcium deficits. The interaction of
vitamin D and calcium to maintain bone miner-
alization is such that an adequate intake of either
one will compensate to some extent for suboptimal
intake of the other. However, rickets can develop
when both calcium intake and vitamin D status
are low, even in the absence of overt biochem-
ical vitamin D deficiency.87 In rickets primarily
due to vitamin D deficiency, 25(OH)D is generally
below 30 nmol/L and often undetectable. In general,
25(OH)D > 30 nmol/L is sufficient for preventing
nutritional rickets in the presence of an adequate
calcium intake.82
Risk factors for nutritional rickets are primarily
the same factors that are associated with vitamin
D deficiency. For example, since people with dark
skin pigmentation require longer duration of UVB
exposure to produce the same amount of vitamin D
as those with lighter skin, the vastmajority of rickets
cases occur in children with dark skin.88,89 Factors
that limit children’s UVB exposure (e.g., staying
indoors, clothing,90 cloud cover, and air pollution)
also raise the risk of rickets. Maternal vitaminD sta-
tus is a dominant determinant of neonatal vitamin
D status,10 and therefore severe maternal deficiency
can result in congenital or neonatal rickets.91,92
Breast milk usually has low concentrations of
vitamin D (40 IU/L or 1 g/L) unless the mother
is receiving high-dose vitamin D supplementation,
so extended breastfeeding can lead to rickets in
otherwise low-risk infants or infants with minimal
sunshine exposure, unless the infant receives
vitamin D supplementation or complementary
foods with vitamin D and calcium.88,93
Nutritional rickets has been widely reported in
tropical countries of Africa and the Indian sub-
continent, where sunlight is abundant but cal-
cium intakes may be very low.94–96 In contrast to
vitamin D–deficiency rickets, which can present
in the first year of life, calcium-deficiency rick-
ets more commonly presents after the first year,
particularly in settings where dairy intake is lim-
ited. During infancy, the infant’s calcium require-
ments can usually be met by breast milk or infant
formula.38 From 1 to 4 years of age, the estimated
average calcium requirement is approximately
500 mg/day,97 and this intake level should be suffi-
cient to prevent calcium-deficiency rickets in most
children.
Nutritional rickets is effectively treated with
the combination of oral vitamin D and calcium
for at least 12 weeks until healing is confirmed
radiographically.98 Common dosing is 2000 IU/day
of vitamin D and 500 mg/day of elemental calcium,
although this may vary on the basis of etiology and
response, and some children require a longer dura-
tion of treatment.35 Daily doses of vitamin D2 or
D3 are equally effective, but vitamin D3 may be pre-
ferred for single large doses owing to its longer half-
life.99 Vitamin D is preferentially given orally but
may also be administered by intramuscular injec-
tion if necessary.35
The IOM and the Global Consensus Recom-
mendations on Prevention and Management of
Nutritional Rickets recommend vitamin D intakes
of 400 IU/day in infancy to prevent nutritional rick-
ets and vitamin D deficiency in otherwise healthy
infants with adequate calcium intakes.35,38 After 12
months of age, the IOM recommends an intake of
600 IU/day (RDA) for children, adolescents, and
adults through supplementation or fortified foods,
assuming minimal endogenous production from
sunlight exposure. These intakes are likely suffi-
cient to maintain 25(OH)D concentrations above
50 nmol/L in most healthy children,67,100 thereby
essentially preventing rickets. IOM recommenda-
tions for women of childbearing age, including
during pregnancy, are the same as the general rec-
ommendations for adults (600 IU/day). Maternal
prenatal intakes of at least 400 IU/day are expected
to be sufficient to prevent congenital rickets;
however, other benefits to the woman or newborn
are unclear (discussed in further detail below).
In summary, nutritional rickets is a preventable
disease with serious health consequences. Public
health strategies to ensure adequate vitamin D and
calcium intakes in infancy and early childhood can
help to eradicate nutritional rickets. Targeting at-
risk groups can mitigate the burden of disease, and
case identification can be useful for monitoring the
effectiveness of rickets prevention efforts.
Although numerous studies have addressed the
relationship between vitamin D status and indica-
tors of bone health (e.g., bonemineral content, frac-
tures, and intestinal calcium absorption) in children
and adolescents without rickets (e.g., Refs. 101,102),
working group members did not identify new evi-
dence related to these outcomes that warranted a
modification to the general agreement on 25(OH)D
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cut-points or dietary intake recommendations for
young children.
Osteomalacia and bone health in older adults
Osteomalacia is a bone disease in adults that results
fromdefectivemineralizationdue to inadequate cal-
ciumorphosphorus availability or excessive calcium
resorption frombone,most commonlydue to severe
vitamin D deficiency. Osteomalacia is the adult dis-
ease most similar to rickets in children; however,
the majority of research into the effects of vitamin
D deficiency onmusculoskeletal health in adults has
considered falls, osteoporosis, and their consequent
risksof fractures as theprimary functional outcomes
of interest,103 largely because of the large overall
contributions of these conditions to morbidity and
healthcare costs in high-income countries.104
Several large studies of vitamin D in older
adults—the InCHIANTI study with participants
in Chianti, Italy;105 the Progetto Veneto Anziani
(Pro.V.A.) study with participants from Northeast-
ern Italy;106 the National Health and Nutrition
ExaminationSurvey (NHANES) III;107 and theLon-
gitudinalAgingStudyAmsterdam(LASA)108—have
shown a relationship of low 25(OH)D to physi-
cal performance measures. A possible mechanism
by which vitamin D may influence the risk of falls
is through its effects on muscle strength, muscle
function, and balance, but this could be due to
reverse causality. RCTs of vitamin D supplemen-
tation on physical performance are inconsistent; a
recent meta-analysis found that the most signifi-
cant effect of vitamin D supplementation on mus-
cle strength was in those over 65 years with baseline
25(OH)D levels lower than 30 nmol/L, although the
overall effect size was small.109
The role of vitamin D in adult bone health has
been amajor focus of research inhigh-incomecoun-
tries; however, the working group considered that
the inconsistent evidence of benefits of vitamin D
in the prevention of falls or fractures in older adults
suggested that these conditions would be unsuit-
able as proxy indicators of population vitamin D
deficiency or as indicators of the response to public
health interventions such as vitamin D fortification
or supplementation.6
Pregnancy and lactation
Vitamin D–deficient mothers give birth to babies
who are themselves deficient in vitamin D and
are thus at risk of hypocalcemia and congeni-
tal rickets.91,92,110 While many pregnant women in
high-income countries take prenatal vitamins con-
taining at least 400 IU/day of vitamin D, the WHO
does not currently recommend routine supplemen-
tation of pregnant women other than to treat vita-
min D deficiency.111 Anecdotally, physicians and
researchers working in countries where rickets is
prevalent often support routine maternal supple-
mentation with vitamin D during pregnancy to
ensure a minimum total intake of 400–600 IU/day,
including supplements.
Over the past 20 years, there have been numer-
ous studies probing the potential effect of maternal
vitamin D status on pregnancy complications, such
as pre-eclampsia and preterm birth, and birth and
early infant outcomes including low birth weight
and stunting in the first year of life. In 2016, a
Cochrane Review found evidence that vitamin D
supplementation during pregnancy may reduce the
risk of pre-eclampsia, preterm birth, and low birth
weight.10 Yet, the evidence has been insufficient to
prompt the WHO to recommend supplementation
during pregnancy to protect against these adverse
outcomes. An updated systematic review and meta-
analysis, including trials published up to September
2017, did not support earlier findings of an effect
of prenatal vitamin D supplementation on preterm
birth but did suggest the following potential bene-
fits: increase in mean birth weight, reduced risk of
small-for-gestational age (SGA), increase in length
at 1 year of age, and a reduced risk of offspring
asthma or recurrent/persistent wheeze up to 3 years
of age.9
The working group agreed that there is a need
for additional RCTs that are carefully designed and
adequately powered to yield precise estimates of the
dose-dependent effects of prenatal and/or postpar-
tum vitamin D supplementation on key maternal
and infant outcomes of public health relevance,
including pre-eclampsia, gestational diabetes,
preterm birth, SGA, low birth weight, and postnatal
infant growth. Some trial findings suggest that vita-
min Dmay have effects on fetal and infant growth,9
which suggests that improvements in prenatal
vitamin D status could contribute to reductions in
the prevalence of low birth weight and stunting, two
of theWHO nutrition targets for 2025.112 However,
a large placebo-controlled dose-ranging trial of
prenatal (beginning in the second trimester) and
postpartum maternal vitamin D supplementation
57Ann. N.Y. Acad. Sci. 1430 (2018) 44–79 C© 2018 The Authors. Annals of the New York Academy of Sciences
published by Wiley Periodicals, Inc. on behalf of New York Academy of Sciences.
Vitamin D deficiency: a roadmap for action Roth et al.
in Bangladesh showed no effects of vitamin D on
fetal or infant growth parameters.113 Nonetheless,
new trials with earlier initiation of supplementation
(first trimester or periconceptional) may be consid-
ered in other settings where fetal growth restriction
and linear growth faltering are prevalent (i.e., South
Asia and Africa). Trials are expected to have the
greatest impact in populations in which vitamin
D deficiency in pregnancy is highly prevalent;
alternatively, women with vitamin D deficiency
could be specifically targeted for trial participation.
The working group highlighted the importance
of interactions of vitamin D with other nutrients
(e.g., vitamin A, calcium, magnesium, folate, and
iron) during pregnancy and lactation. It is expected
that the effect of prenatal vitamin D on skeletal
outcomes (including linear growth and the risk of
rickets in infants) may depend on calcium nutri-
ture. Furthermore, prenatal calcium supplementa-
tion (1–2 g/day) has been shown to reduce the risk
of pre-eclampsia114 and is currently recommended
by the WHO in settings of low dietary calcium
intake.111 Factorial-design trials to directly exam-
ine combined vitamin D–calcium effects on mater-
nal and infant outcomes would be ideal but would
entail substantial complexity and cost.
Vitamin D is secreted into breast milk, but the
concentration depends on the lactating woman’s
regular vitamin D intake. High-dose maternal
supplementation (4000 IU/day or higher) may
be required to boost vitamin D content in breast
milk enough to ensure that the equivalent of
200–400 IU/day is transferred to the exclusively
breastfeeding infant.115,116 In both high- and lower-
income countries, maternal supplementation may
be preferred to infant supplementation; for exam-
ple, mothers in a U.S. study preferred supplement-
ing themselves rather than offering a supplement
to their baby.117 Maternal supplementation may
also be viewed by public health officials in many
contexts as being consistent with efforts to promote
exclusive breastfeeding.
The present working group supported further
clinical research, including dose–response RCTs, to
establish a safe and effective maternal postpartum
vitamin D supplementation regimen that could be
offered as an alternative to direct infant vitamin D
supplementation. In settings where early childhood
rickets is a public health concern (i.e., prevalence
>1%) but infant vitamin D supplementation is not
yet guided by national policies (i.e., South Asia),
the introduction of maternal postpartum supple-
mentation may offer considerable advantages with
reference to public and professional acceptance and
adherence in the context of ongoing broad-based
efforts to promote exclusive breastfeeding.
Acute respiratory infections, asthma, and
tuberculosis
Strong evidence recently emerged linking vitaminD
deficiency to adverse respiratory outcomes, partic-
ularly asthma exacerbations118,119 and tuberculosis
(TB) reactivation, likely mediated by the immune
modulatory effects of vitamin D.120 Recent meta-
analyses show that vitamin D supplementation can
decrease the frequency of upper respiratory infec-
tions (URIs)3 and asthma exacerbations.119,121 ARIs
are the most common form of infectious disease in
children under 5 regardless of economic status.122
Upper respiratory infections constitute most cases,
and, while they are not a significant cause ofmortal-
ity, economic and productivity losses due to illness
are significant. Acute lower respiratory infections
(LRIs) cause an estimated 2.8 million deaths per
year, and TB causes 1.7 million deaths per year.123
An estimated 300 million people worldwide live
with asthma, and 250,000 people die annually from
complications of the disease, primarily from acute
asthma attacks (termed exacerbations).124 Thus,
reducing the disease burden from respiratory infec-
tions and asthma could have a significant global
impact in lowering overall mortality.
Vitamin D may have a role in the prevention of
ARI and asthma exacerbations or as an adjunctive
therapy in patients receiving conventional antimi-
crobial treatment for TB. To date, the majority
of RCTs investigating the efficacy of vitamin D to
prevent ARI have focused on acute URIs rather than
LRIs, despite the fact that LRIs impose amuch larger
mortality burden.124 A recent meta-analysis of IPD
from more than 11,000 participants in double-
blind, randomized, placebo-controlled trials
showed that vitamin D supplementation is effective
in reducing the frequency of URIs and that the
strongest protective effects were evidenced by those
participants who began the study with baseline
circulating 25(OH)D concentrations<25 nmol/L.3
The conclusion that thosewith vitaminDdeficiency
reap the largest benefit from supplementation is
consistent with the lack of effect of higher dose
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vitaminD onURI incidence in a recent randomized
trial of 2000 versus 400 IU/day during the winter
in Canadian children in whom the mean baseline
25(OH)D was high (90 nmol/L).125 However, few
of the trials to date have been conducted in commu-
nities with elevated rates of LRI-related mortality.
Some RCTs of vitamin D for the treatment or pre-
vention of LRIs in children have used intermittent
bolus dosing rather than daily dosing, which may
explain their null results.126–128 The working group
discussed that phase 3 RCTs of daily or weekly
vitamin D supplementation to prevent LRIs in
young children in LMICs are a research priority.
Meta-analysis of vitamin D supplementation
trials for the management of asthma revealed
a significant reduction in the frequency of
asthma exacerbations that required corticosteroid
treatment, as well as a significant reduction in
severe episodes requiring emergency medical
attention.119,121 Protective effects of vitamin D sup-
plementation against asthma exacerbation are likely
to bemediated at least in part by induction of innate
immune responses to respiratory viruses that com-
monly trigger such events. Of note, the majority of
RCTs contributing to thesemeta-analyses were con-
ducted in patients with mild-to-moderate asthma;
thus, new primary trials are needed to determine
whether vitamin D can also reduce exacerbations
in patients with severe asthma. Meta-analysis of
two recent trials of maternal prenatal vitamin
D supplementation demonstrated a significant
reduction in the incidence of offspring recurrent or
persistent wheeze by 3 years of age;130 follow-up of
these prenatal RCTs for effects on asthma incidence
in the children at 5–6 years is ongoing.
Vitamin D may also have a role in the preven-
tion of Mycobacterium tuberculosis infection, pre-
vention of active TB, or as an adjunctive therapy
to enhance response to antimicrobial treatment of
active TB disease. Two phase 3 RCTs of vitamin
D for the prevention of M. tuberculosis infection
are currently ongoing, one in Mongolia131 and the
other in South Africa;132 results are expected from
2020 onward. A single phase 3 RCT of vitamin D to
prevent active TB in HIV-infected adults is ongo-
ing in Tanzania,133 but RCTs of vitamin D to pre-
vent activeTB inHIV-uninfectedpeople areneeded.
RCTs of adjunctive vitamin D to enhance response
to antimicrobial therapy have tended to yield null
results for sputum culture conversion outcomes in
drug-sensitive disease.128 However, subgroup anal-
yses indicate possible benefits of adjunctive vitamin
D in patients with multidrug-resistant TB.134,135
Global prevalence of vitamin D deficiency
Although several recent review papers have high-
lighted the global extent of vitamin D defi-
ciency, there are significant data gaps, especially
for LMICs.57,136–138 Representative population-level
25(OH)D data are not available for most coun-
tries, and the surveys that do exist often present
an incomplete picture of vitamin D status and
its determinants (i.e., lacking complementary data
related to dietary intake, UVB exposure). Addition-
ally, as described above, 25(OH)D may be mea-
sured using several different assays that vary in their
accuracy and precision, and so results vary widely
betweenassays andbetween laboratories.The lackof
standardization in laboratory methods complicates
efforts to synthesize population-level data or make
comparisonsbetween studiesover time.Direct com-
parisons between studies are further complicated by
the way data are reported and cutoffs are used (e.g.,
percent of the population below 30 nmol/L versus
below 50 nmol/L).
Available data from a recent review of vitamin
D status worldwide suggest widespread vitamin D
deficiency, regardless of a country’s human devel-
opment index and latitude; in some cases, vitamin
D deficiency persists despite fortification policies
that aim to ensure adequate intake57 (see below
for discussion of the challenges with fortification).
Unfortunately, data regarding vitamin D status and
prevalence of deficiency were mainly from out-
dated (>10 years old) and/or relatively small studies
of selected samples, rather than large representative
population-based surveys. Nonetheless, there was
consistent evidence suggesting that the prevalence
of vitamin D deficiency is highest in Asia, the Mid-
dle East, and Africa, as well as among immigrants
from these regions living in countries at higher
latitudes.139 It should be noted that calcium intake
tends to be low in these regions, increasing the risk
of rickets and other bone diseases related to vitamin
D deficiency.84,94,95 Numerous small studies in Asia
have found that the majority of young infants have
25(OH)D below 30 nmol/L: for example, 51% of
infants in Turkey, 86% of infants in Iran, 61% in
India, and 61% in Pakistan.57 In studies that were
not population based, pregnant and/or lactating
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Table 3. Data on serum 25(OH)D levels in infants, adults, and pregnant or lactating women in selected countries on
the basis of a systematic review of published studies57
Country Survey year(s) N <30 nmol/L <50 nmol/L
United States
Infants229
Adults230
Pregnant/lactating women231
1997–2001
2001–2006
2001–2006
400
23,424a
928
—
6%
—
46% (black), 10% (white) (<37.5 nmol/L)
34–37%
33%
India
Infants232
Adults233
Pregnant/lactating women232
2006–2007
2010
2006–2007
342
441
541
61%
—
60%
99%
66%
96%
Iran
Infants59
Adults234
Pregnant/lactating women59
2002
2010
2002
258
1111
552
86%
—
—
93% (<35 nmol/L)
51%
67% (<35 nmol/L)
Turkey
Infants58
Adults
Pregnant/lactating women58
2008
—
2008
258
—
258
51%
—
50%
90%
—
90%
aIndicates data are nationally or regionally representative.
women in Asia and the Middle East have also been
found to have high risks of deficiency: for example,
50% in Turkey, 45% in Pakistan, and 60% in India.
Table 3 shows the vitamin D status data for a
few selected LMICs where substantial 25(OH)D
data are available, using the United States as a
comparison.57
Studies in LMICs that have examined differences
between men and women (Jordan, Sri Lanka,
Vietnam, Mexico, and Nigeria) or boys and girls
(Mexico andMalaysia) have consistently shown that
women and girls had lower average 25(OH)D than
their male counterparts. This is largely thought to
be based on differences in occupation, clothing, and
cultural practices that predispose women in these
countries to lower vitamin D status rather than
biological differences in vitamin D metabolism
between males and females.57
A population’s burden of vitamin D deficiency
can also be evaluated on the basis of prevalence
of rickets in childhood and early adolescence
(<15 years old). The prevalence of nutritional
rickets appears to be greatest in Asia, the Middle
East, and Africa, ranging from 1% to 24% in
children.82,140–143 However, nutritional rickets has
recently re-emerged in high-income countries
(Table 4), with prevalence figures ranging from 3
to 120 per 100,000 children.88,139,144,145 In high-
income countries, the overall increasing prevalence
of rickets may correspond with an increase in ethnic
minority, immigrant, and refugee populations,
with reported prevalence rates of 60–2300 per
100,000.146 Less is known about the prevalence of
the acutely life-threatening complications of nutri-
tional rickets, such as hypocalcemic seizures78,147
and cardiomyopathy.148,149 Rickets surveillance
programs, particularly in LMICs, would signif-
icantly improve these estimates and enable the
identification of communities with the greatest
need for a vitamin D intervention.
Groups at highest risk of vitamin D deficiency
Vitamin D deficiency affects individuals in all age
groups worldwide; however, diet, supplement use,
age, geographic latitude, cultural and lifestyle fac-
tors, skin pigmentation, and individual differences
in vitamin D metabolism increase or decrease
individual risk of deficiency.26,57,146,150 Exclusively
breastfed infants, dark-skinned individuals, older
adults, and people with habitually limited sun expo-
sure are at particularly high risk for vitamin D
deficiency.82,151,152
ThevitaminDstatusof infantsdependsonmater-
nal prenatal vitamin D status, intake of breast milk
and its vitamin D content (40 IU/L unless women
have large intakes of vitamin D during lactation),
sunlight exposure, and vitamin D supplements.151
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Table 4. Prevalence of rickets in selected high-income
countries, overall and among high-risk groups of chil-
dren with dark skin pigmentation (including immigrant
and refugee groups)146
Incidence of rickets (per 100,000)
Country Overall High-risk groupsa
Unites States 24 220
United Kingdom 8 95
Australia 5 2300
Denmark 3 60
aHigh risk refers to dark-skinned children (including immigrants
and refugees) living in high-income countries, according to the
authors of the source publication.146
As safety concerns and cultural norms typically limit
infant exposure to sunlight, infants are particularly
vulnerable to deficiency during the first year of life
if maternal vitamin D status is not adequate and
if neither infants nor their breastfeeding mothers
receive supplements.54
Skin pigmentation and lifestyle are important
determinants of vitamin D status. Darker skinned
individuals require longer periods of exposure to
UVB to generate a given amount of vitamin D com-
pared with lighter skinned individuals.153 Regard-
less of natural skin pigmentation, use of sunscreen
or wearing clothing that covers most of the skin can
contribute to low 25(OH)D.154 Older adults with
limited mobility are also at risk, as are individuals
who spend most of the day indoors.106,108
It is estimated that one minimal erythemal dose
of UV radiation, resulting in a slight pinkness to
most of the body, yields 10,000–25,000 IU of vita-
min D.155 However, numerous ecological factors
including high latitude and poor air quality may
attenuate UVB exposure. Cities at latitudes >35°
receive little or no UVB radiation during winter
months (the duration of this “vitamin D winter”
period increases with increasing latitude), making
vitamin D synthesis from sunlight nearly impos-
sible, even when skies are clear.156 In regions with
ample year-roundUVB exposure, dense cloud cover
or atmospheric pollution can interfere with vitamin
D synthesis.157,158 Theworking group therefore con-
cluded that there is a significant risk of vitamin D
deficiency in populations living in tropical or rela-
tively low-latitude countries, which includes most
LMICs.
Interventions to reduce the prevalence of
vitamin D deficiency and related diseases
Thehighprevalenceof vitaminDdeficiency inmany
countries has led to the development and imple-
mentation of a variety of food fortification and
supplementation policies and programs aimed at
reducing the burden of vitamin D deficiency, and in
particular the prevalence of childhood rickets.
Fortification of staple foods with vitamin D
Fortification is a recommended strategy to improve
population micronutrient status.159 The working
group agreed that fortification of food with
vitamin D would be an effective population-based
approach to closing the gap between current
recommendations and population intakes. As
with all fortification initiatives, the identification
of a widely consumed, fortifiable, and culturally
appropriate vehicle is essential to ensure the success
of a vitamin D fortification program.
Mandatory versus voluntary fortification. For-
tification can be included in national legislation as
mandatory (i.e., 100%of the identified foodproduct
must be fortified by law) or voluntary (i.e., industry
is at liberty to make the decision to fortify the
specified food but must comply with the required
level of fortification if they choose to fortify).159
Government-mandated fortification of a food
staple is the most effective method of increasing the
dietary intake of a particular nutrient in the general
population.159,160 Currently, there is mandatory
vitamin D fortification of milk and infant formula
in Canada, and the United States mandates vitamin
D fortification in nonfat dry milk, evaporated milk,
and infant formula. These policies have been under
government regulation for over 40 years in Canada
and almost 90 years in the United States.161 This
approach has proved effective in the prevention of
most cases of rickets.162,163 Effective fortification
programs depend on industry compliance, which
is most readily achieved when compliance is
incentivized and enforced. Government oversight
can also ensure a safe level of fortification with
appropriate formulations of vitamin D.164
Voluntary fortification is less likely to produce
an impact on micronutrient status, as it does not
create a level playing field for food producers,
thereby increasing the risk that industry may focus
on higher cost or niche products rather than ones
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aimed at higher risk consumers who have limited
vitamin D intake from other sources.165 Voluntary
or discretionary food fortification has been shown
to be less effective in reaching entire populations in
LMICs, such as in India, in part becausemany staple
foods are procured from numerous small-scale
suppliers rather than from a small number of
centralized producers.166 Voluntary fortification in
high-income countries has also been shown to be
less reliable and can result in misguiding consumers
to over- or underconsume vitamin D, as variations
in vitamin D content can occur among similar food
products from different manufacturers.167,168
Approach to the selection of food staples for
mandatory fortificationwith vitaminD. Careful
selection of food vehicles for mandatory fortifica-
tion is critical to ensure that a substantial proportion
of the population regularly acquires and consumes
the foods to be fortified. Establishing the predomi-
nant pattern of food or ingredient use in a country
is crucial before selecting a food vehicle for forti-
fication (Fig. 4).169 Optimal food vehicles selected
to deliver adequate dietary vitamin D to the major-
ity of the population are those that are frequently
consumed population wide, affordable, and acces-
sible in both urban and rural areas. Ideally, there
should be low variability in the amounts consumed
to limit the risk that some individuals may con-
sume more than the tolerable UL of the nutrients
included in the fortification program. Foods need to
be industrially processed andwidely distributed by a
reasonably small number of manufacturers to facil-
itate proper training and continued monitoring of
industry compliance. Inmany LMICs, amajor chal-
lenge is that food staples and/or food ingredients are
often produced bymultiple small-scale producers or
in the households themselves, which are less likely to
be able to participate in either voluntary or manda-
tory fortification schemes. Other important consid-
erations include the vitamin D stability during pro-
cessing, cooking, and storage of the fortified food
staple. Similarly, it is important to anticipate the
storage conditions of the food at point of purchase.
InLMICs,manymarkets sell small quantities of food
frombulk sacks or drums, potentially incurringpro-
longed storageunder conditions that are suboptimal
for the stability of fortificants. An additional bene-
ficial property of a vehicle is its suitability for cofor-
tification with vitamin A, calcium, and/or other
limited micronutrients of interest for public health
programs. Detailed country- or region-specific data
about the types and frequency and amounts of con-
sumption of candidate foods (dietary intake pat-
terns), and the extent to which the products will
reach the entire population and targeted subgroups,
are needed to select an acceptable food for forti-
fication in each context.170,171 Country or region-
specific information about current vitaminD intake
levels are also needed to set appropriate levels of
fortification. The vitamin D used in the fortifica-
tion premix must be bioavailable and effectively
delivered, meaning that typical consumption pat-
terns result in appropriately increased mean serum
25(OH)D concentrations. Other important issues
include the vitamin D stability during processing,
transport, storage (in the market and the home),
and cooking of the fortified food item (see below).
Primary considerations for food fortification
vehicles learned from surveys in LMICs include
the following. (1) Knowledge of food consump-
tion is necessary to inform fortification programs.
Thus, food vehicles for fortificationmust be selected
on the basis of estimates of the proportion of the
population likely to be reached and origin of the
foodusedbyhouseholds. (2)Consumptionpatterns
vary widely among countries, regions, and socioe-
conomic groups within countries; therefore fortifi-
cation programs should be designed on the basis of
local food consumption patterns, and not extrapo-
lated from data from other contexts. (3) Fortifica-
tionprograms,with few exceptions, require ongoing
regulatory monitoring and enforcement to ensure
high levels of industry compliance with fortification
(Fig. 4).168–171
Fortifiable vehicles. Vitamin D (as D2 or D3) has
been successfully added to a number of lipid-rich
or nonlipid-containing food vehicles. At the con-
centrations required for fortification of many com-
mon vehicles, the fortificant ideally should have no
adverse organoleptic properties. VitaminD is a rela-
tively stable micronutrient suitable for fortification,
although it is light sensitive, and some losses occur
during cooking. Both vitaminsD2 andD3 have been
shown towithstandbaking andcooking at high tem-
peratures, but the magnitude of loss depends on the
cooking method and the type of food vehicle.172
Dairy. Milk is the most commonly fortified food
for vitamin D in many high-income countries,
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Figure 4. Edible oil that is used, fortifiable, and fortified with vitamin A. Examples of household utilization of edible oil (dark
gray bars), as reported in the Fortification Assessment Coverage Toolkit (FACT) surveys, by potential for fortification (fortifiable,
light gray bars), and actual content of fortificant (fortified, white bars).169 Oil fortification was voluntary in India but mandatory
in all other settings shown. Adapted from Aaron et al.169
largely because it is widely consumed by children
and a good source of calcium.173,174 However, dairy
intake is low in many countries where vitamin D
deficiency is common, notably in the Middle East
and parts of Africa.146,175 Even where dairy con-
sumption is culturally acceptable, the low avail-
ability and affordability of dairy products suggest
that dairy may be limited in its utility as a vehi-
cle for improving vitamin D intake in many low-
income or isolated populations.176 Technological
barriers to safe and accurate addition of vitamin
D to fresh milk may also exist in some countries,
whereas smaller local dairy producers may not be
able to affordandcorrectlymanage the sophisticated
equipment required to add and evenly distribute
vitamin D accurately. Of note, the only recorded
case of vitamin D toxicity arising from fortification
in the United States occurred in a small dairy facil-
ity when vitaminDwas addedmanually in excessive
unmeasured amounts and not properly mixed for
evendistribution.177 However, shelf-stablemilkmay
overcome some of the challenges by allowing cen-
tral facilities to produce large quantities of milk that
can be widely distributed with fewer risks for safety
and stability. For example, one study showed that
fortification levels of 100 and 250 IU of vitamin D
per serving of 2% fat ultra-high-temperature pas-
turized milk were stable over the 60-day shelf life of
the product.178
Edible oils. VitaminD fortification of foods other
than dairy products has been used as an alternative
approach in countries where dairy consumption is
low because of cost, intolerance, or other factors.179
Water-soluble forms of vitamin D have been devel-
oped and are used in North America to fortify fruit
juices that are also cofortified with calcium.180 Edi-
ble oils are important candidate vehicles for forti-
fication in many LMICs, as they are centrally pro-
cessed, broadly distributed, and widely consumed
by all age groups. However, little is known about the
long-term stability of vitamin D added to various
edible oils. In one study of soybean oil, vitamin D3
content declined substantially during storage; losses
after 2 months were as high as 68% in natural light
but only 44% in semidarkness. Vitamin E appeared
to promote vitamin D retention, particularly for
samples stored in semidarkness.181 Therefore, stor-
age in semidark conditions and with higher antioxi-
dant content, such as vitamin E, is likely to promote
vitamin D stability when added to edible oils.
In a recent analysis of coverage of vitamin A–
fortified or fortifiable oil in some LMICs, edible oil
was reportedly used by the majority of households
across Africa and in India.169 Across all surveys,
except Abidjan, considerable effort is still required
to enforce the fortification program (assessed in this
survey for vitamin A content only). As fortification
of oilwith vitaminA is voluntary inRajasthan, itwas
not surprising that only a small proportion of edible
oil was actually fortified. These examples illustrate
the challenges in selecting fortifiable vehicles that
are widely consumed as well as the importance of
enforcing mandatory fortification policies.
Cofortification of oil. Theability to cofortify foods
with vitamin D that are already being fortified with
vitamin A may be a cost-effective means to increase
vitamin D status in settings where vitamin A for-
tification is already being implemented. Presently,
36 countries mandate or allow voluntary fortifica-
tion of edible oils with vitamin A alone, and 10
countries mandate or allow voluntary cofortifica-
tion with both vitamins A and D, as shown in the
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Figure 5. Countries where edible oils are fortified with vitamin A (yellow) or vitamins A and D (green).18 While 36 countries
allow fortification of edible oils with vitamin A, 10 countries (Afghanistan, Djibouti, India, Morocco, Mozambique, Oman, Papua
New Guinea, Sierra Leone, Yemen, and Zimbabwe) allowmandatory or voluntary fortification with vitamin A, and mandate edible
oils to include vitamin D as an optional or mandatory cofortificant in their standards.
map in Figure 5. No country mandates or allows
fortificiation of oil with vitamin D without also
mandating or allowing oil fortification with vita-
min A. While cofortification of vitamin A–fortified
foods with vitamin D is widely regarded as a cost-
effective strategy for improving vitamin D intake,
the efficacy of this strategy in raising population
25(OH)D is unknown. Specifically, there are insuffi-
cient data from human studies to determine if com-
bining vitamins A and D in oil impedes, enhances,
or has no impact on bioavailability or absorption
of either nutrient. As edible oils are widely believed
to be good vehicles for vitamin A fortification, and
facilities and processes to support oil fortification
in LMICs are increasingly well established, research
into the efficacy of adding vitamin D to vitamin
A–fortified oils could be conducted to guide recom-
mendations for countries interested in addressing
vitamin D deficiency. As with all fortification pro-
grams, the cost-effectiveness of vitamin D fortifica-
tion programs versus supplementation strategies to
correct vitamin D deficiency in specific population
groups, particularly those living in LMICs, can be
assessed to inform decision making.182
Flours—wheat, rice, and maize. Cereal grain-
based food staples including wheat, rice, or maize
flour, commercially baked goods, and noodles are
fortified in many high-income countries on a vol-
untary basis and have been proposed as suitable
vehicles for mandatory vitamin D fortification in
the United States and some European countries.183
For flour fortification, vitamin D in liquid form is
spray-dried and added as a powder to flour or bak-
ing premixes.184 Clinical trials in Finland, Romania,
and Iran provide solid evidence of bioavailability
and efficacy of vitaminD from fortified bread.185–188
Many studies using vitamin D–fortified wheat or
maize flour in LMICs support the use of these
foods as a vehicle for increasing vitamin D intake.
For example, biscuits made from multinutrient-
fortified wheat flour, which included vitamin D, fed
to Bangladeshi school children significantly reduced
the risk of vitamin D deficiency and other nutrient
deficiencies relative to a control group.189 One of
the few examples of a national wheat flour fortifica-
tion initiative that includes vitamin D is the Jorda-
nian wheat flour fortification program, introduced
in 2009, which mandates vitamin D fortification at
the level of 550 IU/kg (13.75 g/kg) or approxi-
mately 58 IU vitamin D/serving (1.45 g vitamin
D/serving).190 However, the impact of the Jorda-
nian wheat flour vitamin D fortification program
is unclear. Fortification of maize flour with vitamin
D is an alternative approach but has not been well
studied or widely implemented.191
Alternative vehicles and indirect fortification
approaches. Water-soluble forms of vitamin D have
been developed and are used in North America
to fortify fruit juices that are also cofortified with
calcium.180 Other fortification vehicles are under
development using techniques such as bio-addition
to enhance the vitamin D concentration in foods.
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For example, sunlight-exposed edible mushrooms
show good bioavailability of vitamin D2 in rodents
consuming mushroom powder and in humans
consuming intact or powdered light-exposed
mushrooms.192–194 Scientists in Bangladesh and
Africa have proposed using mushroom powder in
cereal grain-based bread to improve protein and
specific B-vitamin intake.195,196 Edible mushrooms
produced from agricultural waste in parts of Africa
andAsia are often sun-dried and ground intomush-
room flour, a light-exposure process that would
also increase the vitamin D2 content of the flour.197
Addition of mushroom flour to bread is an example
of a new method of vitamin D fortification called
bio-addition that utilizes the addition of a food
ingredient or animal feed rich in vitamin D to
increase the vitamin D content of the final food
product, such as eggs or meat or, in the case
of mushroom powder, bread.159 However, the
feasibility and potential for population impact of
this approach has not as yet been tested in LMICs.
Vitamin D supplementation
Supplementation programs can be implemented to
enhance the status of a population, while fortifi-
cation programs are under development to target
specific population subgroups that are inadequately
reached by fortification programs. The high vita-
min D content of cod liver oil was first recognized
in the 1930s, and it remains in use today. However,
many other forms of vitamin D supplements are
now available in the form of tablets, capsules, and
drops (available as single vitamin preparations or
combined with other micronutrients). Vitamin D is
also included in a number of point-of-use multinu-
trient fortification products, such as micronutrient
powders (MNPs) and lipid-based nutrient supple-
ments (LNSs).
Supplementation as a targeted intervention. In
the United States, vitamin D supplement use in the
2009–2010 NHANES was 35%, with one-third of
these supplement users taking a product provid-
ing an amount greater than or equal to the cur-
rent RDA (600 IU/day).198 In a study in Canada,
lower income segments of the population tended to
use supplements less often, even if use would have
been justified because of low vitamin D status.199
However, the global extent of vitamin D supple-
ment use is unknown, and few surveys in LMICs
have assessed vitaminD supplement intake. In 2014,
UNICEF’s Nutridash surveillance system reported
that 50 LMICs had public health preventive pro-
grams distributing MNPs to children 6 months–
5 years of age.200 MNPs often contain vitamin D
in the formulation, including the standard formu-
lation used by UNICEF and the World Food Pro-
gramme, two of the leading global supporters of
MNP programs in LMICs. Recent WHO recom-
mendations for MNP use in children 6 months–
12 years of age suggest that vitamin D can be added
to the formulation up to 100%of the RNI.201 Unlike
traditional supplements, MNP and LNS point-of-
use products are usually mixed into food imme-
diately before serving and thus may be easier to
administer to children.
Supplementation of breast-feeding infants with
400 IU/day is widely recommended and practiced
in many high-income countries including Canada
and the United States.35,38 Nonetheless, WHO does
not currently recommend routine vitamin D sup-
plementation in children.202 WHO also does not
recommend routine vitaminD supplementation for
pregnant women because of a lack of strong evi-
dence of benefits for maternal and fetal health;111
however, vitamin D is included in the supplement
formulations used in emergency situations.203
Dosing regimens for vitamin D supplementation.
Vitamin D supplements may be provided daily,
weekly, monthly, or less frequently as larger bolus
doses. Studies comparing different dosing regimens
have attempted to determine whether vitamin D
supplements given at different intervals are equiva-
lent in maintaining levels of 25(OH)D. Ish-Shalom
et al. found that daily (1500 IU), weekly (10,500 IU),
or monthly (45,000 IU) doses all produced similar
rises in 25(OH)D.204 By contrast, Chel et al., using
lower doses of vitamin D (600 IU daily; 4200 IU
weekly; 18,000 IU monthly) among older adults in
a long-term care facility, concluded that while all
increased 25(OH)D relative to placebo and that dif-
ferences across groups were minor, there was a dis-
tinct order of efficacy (daily>weekly>monthly>
placebo), likely related to differences in adherence
to the regimens.205
It has been argued that less frequent bolus doses
of vitamin D (anything other than daily) might
adversely affect tissue distribution of vitamin D
in ways that are not captured by measuring only
serum levels of 25(OH)D.206 This viewpoint was
articulated in response to a well-publicized study
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that showed that older women who received annual
bolus dosing of 500,000 IU vitamin D for 3–
5 years experienced more falls and fractures
than the placebo group.74 On the other hand, a
systematic review and meta-analysis of vitamin
D intervention trials concluded that high-dose,
intermittent vitamin D therapy did not affect
all-cause mortality among these older adults 65
years of age, nor was there any impact (benefit or
adverse effect) observed regarding fractures or fall
prevention, when compared to either no treatment
or placebo.207 Of note, one study involving a single
intramuscular injection of 600,000 IU revealed
significant beneficial effects on functional neuro-
muscular performance, reaction time, and balance
after 6 months, although muscle strength or inci-
dence of falls did not improve.208 It is possible that
the route of administration (parenteral versus oral)
may affect the safety and efficacy of large bolus doses
of vitamin D, but at present, it appears that dosing
intervals of monthly or more frequently are more
reliable and safer for attaining target 25(OH)D
concentrations.
Adherence to supplementation regimens. Oral
vitamin D supplementation is effective at raising
25(OH)D to target levels within a few months,
but poor adherence with long-term vitamin and
mineral supplementation regimens and cost to
consumers may limit their practicality. Adherence
is influenced by a range of individual, social, and
environmental factors, including the personal
beliefs and motivation of individuals, their fami-
lies, and social networks; influence of healthcare
workers and others involved in program delivery;
and structure of the local healthcare system.
Supplementation interventions generally require
concomitant behavior change activities to encour-
age families to appropriately use and benefit from
the interventions.209,210 Public education on the
risks associated with severe vitamin D deficiency,
including rickets, may improve uptake in the
general population. Additional potential strategies
to simplify regimens and increase adherence with
supplementationmay include the use of higher dose
weekly or monthly vitamin D regimens rather than
daily supplementation; incorporation of high-dose,
intermittent vitaminD supplements into childhood
primary healthcare programs or routine immuniza-
tion visits (see below);211–214 and supplementation
of lactating mothers with high-dose vitamin D
instead of direct infant supplementation.215
Incorporating vitamin D supplementation into
childhoodvaccinationprograms. Administering
vitaminD supplementation through childhood vac-
cination programs is a supplementation method
that avoids someof the adherence challengesofmore
frequent dosing. High-dose vitamin A supplements
have been successfully combined with immuniza-
tion campaigns administered to infants/children
older than 6 months of age to provide a sustainable
channel for delivering critical nutrients to children
in developing countries. The safety and efficacy of
vitamin A have been well studied in combination
with vaccines, but adequate studies to guide poten-
tial adoption of this model for delivery of vitamin
D have not been conducted as extensively.216
Several studies have investigated the potential
impact of vitamin D status on vaccine response,
including influenza217,218 andBCGvaccines,219 with
mixed findings. Additional research is required to
clarify these relationships and to determine whether
high-dose vitamin D codelivered with vaccines
hinders, enhances, or has no effect on the safety
and long-term effectiveness of childhood immu-
nizations. In particular, the effects of vitamin D
supplementation onhost response to immunization
are poorly understood, and controlled studies in
populations with a range of baseline 25(OH)D con-
centrations are needed to evaluate effects of vitamin
D supplementation in response to vaccines designed
to elicit both humoral and cell-mediated protection.
In summary, the working group supports
fortification as the preferred method to increase
a population’s vitamin D status. Fortification
of widely consumed fortifiable vehicles is most
effective when the program is mandatory and
enforced. The working group agreed that supple-
mentation may be important for identifiable target
populations (e.g., breastfed infants) and in settings
where fortification is impractical.
Roadmap for action: a stepwise approach
Raising both public and professional awareness of
the risk factors and consequences of deficiency is
essential to ameliorating the disease burden caused
by vitaminDdeficiency inLMICs.Numerous expert
panels, including the present working group and
the recent Global Consensus Recommendations on
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Table 5. International and national levels of awareness and action
International Organizations National Organizations
(WHO, UNICEF, CDC, NI, FFI, and GAIN) (Ministry of Health and relevant agencies)
Assessment Identify the need for surveys and provide
technical assistance
Define priorities and initiate assessments
Intervention Provide technical assistance in designing and
implementing programs
Provide a regulatory framework or policies
for fortification or supplementation
programs
Monitoring and evaluation Compile global data
Establish standardization procedures and
best practices
Update national data
Compliance, monitoring, and quality control
of fortification or supplementation
programs
WHO, World Health Organization; UNICEF, United Nations Children’s Fund; CDC, Centers for Disease Control and Prevention;
NI, Nutrition International; FFI, Food Fortification Initiative; GAIN, Global Alliance for Improved Nutrition.
Prevention and Management of Nutritional Rick-
ets, seek to draw attention to these issues and how
they can be solved through fortification and supple-
mentation. Collaboration among international and
national organizations will enable the estimation
of the prevalence of vitamin D deficiency, planning
and implementation of appropriate context-specific
interventions, andmonitoring and evaluation of the
effectiveness of the programs (Table 5).
The working group advocated a stepwise
approach for assessing vitamin D status and
preventing vitamin D deficiency. The first step aims
to establish the prevalence of vitamin D deficiency
using 25(OH)D data from a representative sample
of the population. In the absence of such data, other
types of information can be used to judge whether
the population as a whole or particular subgroups
may have elevated risks of vitamin D deficiency
(Fig. 6).
Quantifying the prevalence of vitamin D
deficiency
Biomarker assessment. Assessment of the vita-
min D status of a population should be primarily
based on recent (i.e., within 10 years) nationally
or subnationally representative serum or plasma
25(OH)D concentration data. The 25(OH)D data
should be standardized as per the Vitamin D Stan-
dardization Program protocol to allow for compa-
rability with prevalence data internationally, as this
protocol seeks to minimize assay-related differences
in the measurement of 25(OH)D.220 The primary
use of such data is to estimate the prevalence of
vitamin D deficiency (i.e., percent of the popula-
tion with 25(OH)D < 30 nmol/L) and (if possible)
in subsets of the population considered especially at
risk (e.g., infants and pregnant women)). Thework-
ing group suggested as a general principle that an
overall prevalence>20% of 25(OH)D< 30 nmol/L
should prompt consideration for an intervention.
The rationale for selecting the 30 nmol/L thresh-
old was described above, and the consideration of
a prevalence of >20% is based on the conventional
practice by the WHO to consider the burden of a
micronutrient deficiency to be moderate/severe if
>20%. Even when the prevalence is less than 20%,
specific high-risk population subgroups are likely to
benefit from interventions.
As noted earlier, representative 25(OH)D data do
not yet exist for most LMICs. Several resources are
available to assist countries in conducting vitamin
D status assessment surveys (Table 6). For example,
the DEQAS can assist with ensuring high-quality
laboratory analyses, and the VDSCP provides lab-
oratory standards. Other organizations have also
published more general tools and databases, such
as the CDC and Nutrition International’s Micronu-
trient Survey Toolkit, WHO’s Vitamin and Min-
eral Nutrition Information System (VMNIS) data
repository.221 TheWHO also provides resources for
monitoring and evaluating interventions with vita-
min and mineral nutrition outcomes.222
Rickets prevalence. In the absence of vitamin D
deficiency prevalence estimates based on surveys
that involve 25(OH)D assessment, the incidence
of rickets can be used as a reasonable surrogate
indicator of vitamin D deficiency within the popu-
lation. The general agreement of the working group
was that a >1% prevalence of X-ray confirmed
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Figure 6. Schematic representation of the Roadmap for Action.
rickets in infants/children may warrant a public
health response; however, the group acknowledged
that the specific threshold for action is arbitrary.
Moreover, if the prevalence is suspected to be greater
than 1% (e.g., pediatricians report frequent cases
of rickets), community surveys to identify children
with clinical features of rickets may be an effective
method to quantify the burden of nutritional
rickets in a population. Then, if the prevalence
is confirmed to be >1%, urgent public health
intervention may be warranted.
Making rickets a reportable disease permits the
estimation of both prevalence and incidence in low-
prevalence regions. Case reports from sentinel cen-
ters can be used to estimate the incidence of new
cases in a population and help determine the need
for more careful examination of population-level
vitamin D status. Previous prevalence surveys of
rickets have used various clinical signs and have not
always confirmed the diagnosis with radiographs.
However, on the basis of a validated study of clinical
features alone, it can be determined if a child is likely
to have active rickets on radiographs.77
UVB exposure. Satellite data may be used to
model the availability of UVB radiation of sufficient
strength to support dermal vitamin D synthesis
for all or some part of the year for a particular
geographic location, even if UVB availability is not
measured by the meteorological services within
individual LMICs. Using raw satellite data as model
inputs is resource intensive; therefore, as a crude
but more rapid approach, online web resources can
yield percent sunshine estimates throughout the
year for any regions of interest (Table 6).
Importantly, ecological data on UVB irradiance
should be considered in conjunctionwith appropri-
ate insights into regional and gender-specific social,
religious, and culture factors (e.g., dress codes and
sun avoidance) thatmay attenuate the effect of UVB
availabilityonactualUVBskinexposures at the indi-
vidual level. There is nocleardefinition for “healthy”
sun exposure, which would be highly variable on
the basis of skin color and genetics. Thus, many
expert groups cautiously recommend that vitamin
D requirements should be met primarily by a com-
bination of dietary and/or supplemental vitamin D.
Dietary intake. Nationally or regionally represen-
tative data on vitamin D intake in the population
or in population subgroups may provide an addi-
tional source of information by which to determine
the adequacy of vitamin D intake in the popula-
tion, but such data are unlikely to be available for
many LMICs. Some insight into vitamin D supply
for populations in LMICs may be gleaned from the
FAO national food balance sheet analysis.223 These
datamayhighlight low supply of vitaminDowing to
the limited availability of naturally rich food sources
and the lack of vitamin D–fortified foods. It is now
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Table 6. Resources for vitamin D status assessment and interventions
Quality assessment: DEQAS (Vitamin D External Quality Assessment Scheme) is an organization whose objective is to ensure the
analytical reliability of 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) assays. They also provide
certification to laboratories that meet their performance targets: http://www.deqas.org/
Quality assessment: The Vitamin D Standardization-Certification Program (VDSCP) provides standards to laboratories:
https://www.cdc.gov/labstandards/hs_standardization.html
Laboratory resources: The Global Laboratory Directory for the Assessment of Micronutrient Status (accepting information and will
be publicly available soon) is a directory of laboratories that perform micronutrient status assessment, including for vitamin D.
The directory is not an exhaustive source nor is any laboratory endorsed by WHO: https://extranet.who.int/laboratory_directory/
Micronutrient Status Assessment Data Repository: The World Health Organization (WHO) Vitamin and Mineral Nutrition
Information System (VMNIS) Data Repository is a publicly available and searchable database that includes summary results of
population-based status assessment surveys carried out at the national and/or first administrative level in any country:
http://www.who.int/vmnis/en/
Micronutrient Survey Toolkit: The Centers for Disease Control and Prevention and Nutrition International (NI) have compiled
tools for micronutrient status surveys that can take the user from survey planning and design through implementation and data
reporting: http://surveytoolkit.micronutrient.org/
Sunlight availability: Meteorological sources can provide preliminary estimates of the available sunlight in the country:
https://weather-and-climate.com/
Fortification: The Food Fortification Initiative (FFI), the Global Alliance for Improved Nutrition (GAIN), the Iodine Global
Network (IGN), and the Micronutrient Forum have collaboratively developed the Global Fortification Data Exchange, a publicly
available database of food fortification policies and standards: http://fortificationdata.org
Food-based interventions: The ODIN (Food-based solutions for optimal vitamin D Nutrition and health through the life cycle)
project aims to provide high-quality scientific evidence to prevent vitamin D deficiency in European citizens and improve
nutrition and public health through food: http://www.odin-vitd.eu/
also feasible to link such data with the Global Forti-
fication Data Exchange online database to ascertain
whether a country has vitaminD added to vegetable
oils and/or margarine on either amandatory or vol-
untary basis (Fig. 5).
Interventions to reduce the prevalence of
vitamin D deficiency
Where vitamin D deficiency is identified as a
concern broadly or within a specific population
subgroup, authorities should consider primary pre-
ventive interventions to optimize vitamin D status
in the population. As described in detail above, the
working group considered several possible options
in relation to vitamin D interventions in LMICs,
with primary consideration of countries in which
interventions to address vitamin D deficiency have
not yet been introduced. The most appropriate
and viable interventions depend on priorities,
resources, and infrastructure within individual
countries or regions. Theworking group recognized
the logistical advantages of integrating a vitamin D
intervention with other dedicated micronutrient or
public health intervention programs (e.g., vitamin
A fortification, routine vitamin A supplementation,
and childhood immunization); however, there
was wide agreement that this would require
addressing several knowledge gaps, as discussed
above.
The working group discussed the strategies put
forth in theWHO/FAOGuidelines on Food Fortifica-
tion with Micronutrients in relation to the full range
of potential strategies for the control of micronutri-
entmalnutrition, namely (1) increasing thediversity
of foods consumed, (2) food fortification, (3) sup-
plementation, and (4) public health measures.176
Public health measures of a more general nature
(e.g., immunization, malaria and parasite control;
improvement of water and sanitation) are often
helpful to prevent some micronutrient deficiencies
associated with poor overall nutritional status and
with a high prevalence of infection, but specific
information on this possibility is not available for
vitamin D.176 Of the three options that are aimed at
increasing the intake of micronutrients, programs
that deliver micronutrient supplements often pro-
vide the fastest improvement in the micronutrient
status of individuals or targeted population groups,
while food fortification tends to have a less imme-
diate, but ultimately a wider and more sustained
impact and is generally more cost-effective than
other interventions.176
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Table 7. Vitamin D research opportunities
Health outcomes
Pregnancy outcomes
Numerous studies have suggested that vitamin D affects pregnancy and birth outcomes,10 but evidence is conflicting and there is no
consensus on the optimal dose of vitamin D supplementation to maximize the prenatal and/or postpartum maternal and infant
benefits.
Research need: Establish the dose-dependent effects of vitamin D supplementation on maternal and infant outcomes, such as
pre-eclampsia, gestational diabetes, preterm birth, SGA, postnatal infant growth, and infant rickets.
It is expected that the effect of vitamin D on skeletal outcomes (including linear growth and the risk of rickets in infants) depends
on calcium nutriture, and may interact with other micronutrients.
Research need: Investigate the relationship between vitamin D and other nutrients, including calcium, vitamin A, folate, and iron as
they relate to pregnancy outcomes and risk of rickets.
There is concern that recommending infant supplementation may conflict with breastfeeding support and promotion efforts, and
some mothers are concerned about supplementing infants. Maternal supplementation is one alternative, but the optimal dose to
supplement mothers for the health of their infants is not known.
Research need: Determine the optimal dose, regimen, safety, and efficacy for maternal supplementation to optimize 25(OH)D and
prevent rickets in breastfed infants.
Respiratory outcomes
It has been hypothesized that free (nonprotein bound) 25(OH)D plays a role in the immune response in respiratory infections, but
this hypothesis has not been sufficiently studied.
Research need: Investigate whether concentrations of free and/or bioavailable 25(OH)D correlate more tightly with respiratory
outcomes than total 25(OH)D.
Vitamin D supplementation has shown some efficacy in prevention of URIs, but the effects of supplementation on prevention of
LRIs and active TB are not yet known.
Research need: Determine if daily or weekly vitamin D supplementation can prevent LRIs or active TB.
The immune-modulating effects of vitamin D suggest that it could be used as an adjunctive therapy for treating some respiratory
diseases, but this has not been thoroughly tested.
Research need: Establish the efficacy of vitamin D as an adjunctive therapy for treating LRIs or for patients with multidrug-resistant
TB.
Much of the testing on vitamin D in asthma to date has involved patients with mild-to-moderate asthma, in which vitamin D can
reduce asthma exacerbations.119,121 Whether this also applies to those with more severe asthma is not known.
Research need: Determine whether vitamin D can reduce asthma exacerbations in patients with severe asthma.
In studies of vitamin D supplementation in asthma, the greatest benefit has been associated with those patients who had the lowest
25(OH)D status at baseline (<25 nmol/L).119 However, more studies are needed to determine if vitamin D supplementation can
benefit those with lesser degrees of deficiency at baseline.
Research need: Investigate the benefits of vitamin D in asthma treatment to assess whether it is restricted to those with lower vitamin
D status.
Prevalence and surveillance of vitamin D deficiency
Prevalence
There is a general lack of 25(OH)D data in LMICs,57 but the limited existing data suggest that vitamin D deficiency may be a
significant problem in many countries. More data are needed to establish the extent of vitamin D deficiency.
Research need: Increase assessment of 25(OH)D as a biomarker of vitamin D deficiency in nationally representative surveys in
LMICs.
There are limited data regarding vitamin D intake and exposure in LMICs, and improving these estimates will aid in identifying
countries where a 25(OH)D assessment survey is necessary.
Research need: Improve estimates of vitamin D and calcium intake and exposure in LMICs to identify settings where further
assessment of vitamin D status is warranted.
Continued
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Table 7. Continued
Surveillance
As nutritional rickets is an indicator of a larger vitamin D deficiency prevalence, expanding rickets surveillance, especially in LMICs,
would improve vitamin D deficiency data and highlight areas in greatest need of a status survey or an intervention.
Research need: Identify regions with the greatest prevalence of vitamin D deficiency by expanding rickets surveillance to include case
reports and validated clinical signs, especially in LMICs. Consider the potential use of serum ALP as a screening biomarker for rickets.
The increasing recognition of the role of vitamin D in immune and cardiovascular health suggests that there may be an
underappreciated effect of vitamin D deficiency on child mortality.
Research need: Better understand the effects of low vitamin D status and vitamin D supplementation on child mortality, especially
in low-income settings, given that vitamin D is a known immune modulator and that low vitamin D increases the risk of respiratory
infections, and that there may be unknown consequences of vitamin D deficiency.
Vitamin D interventions
Fortification
Cofortification of foods with both vitamin A and vitamin D presents a cost-effective method for fortification in countries with an
existing vitamin A fortification program.176 However, it is unclear whether there are interactions between the two micronutrients
that may affect their efficacy, bioavailability, and/or stability.
Research need: Establish the efficacy of cofortification with vitamins D and A.
Calcium and vitamin D are highly dependent on each other for optimal bone health. However, in many LMICs, it is often not
practical to fortify dairy products, which naturally contain calcium (either because of low consumption or small-scale
production). As calcium can dramatically affect the organoleptic properties of the vehicle, acceptable alternatives to ensure
adequate calcium and vitamin D intake are needed.
Research need: Assess alternative methods of calcium and vitamin D codelivery, especially in countries where dairy consumption is
low.
Bio-addition is a potentially low-cost alternative for increasing the vitamin D content in foods.173 However, these techniques need
further development and have not been assessed for their suitability in LMICs.
Research need: Develop methods to increase the vitamin D content of foods through bio-addition.
Dosage and safety of supplementation
Vitamin D supplementation during routine vaccination provides a good opportunity to ensure that children receive adequate
vitamin D, but the efficacy of delivering relatively large doses with vaccines has not been tested.
Research need: Determine the safety and effectiveness of delivering vitamin D with childhood vaccinations.
Awareness and education
Educating the public about the current recommendations remains an important and ongoing task to ensure the success and public
acceptance of interventions, including supplementation and fortification.
Research need: Design and test approaches to enhancing awareness among the general public of vitamin D recommendations and
the impact of vitamin D on health outcomes.
Ensuring that parents and caregivers of infants and children are well informed about the health consequences of vitamin D
deficiency and current supplementation recommendations (maternal, infant, and child) as important strategies to improve
adherence and ultimately prevent rickets.
Research need: Develop and evaluate social and behavior change strategies to improve adherence to infant and childhood vitamin D
supplementation.
Research agenda
The working group discussed numerous knowledge
gaps and uncertainty related to the role of vitaminD
in specific health outcomes, the efficacy and safety
of vitaminD interventions for particular health out-
comes apart from bone health, and the effectiveness
of large-scale public health implementation of pro-
grams to control vitamin D in low-income settings.
A high-level research agenda (Table 7) was prepared
by the working group to describe these evidence
gaps. It should be noted that the group’s empha-
sis on the need for RCTs of vitamin D interven-
tions in this field, where possible, was not a reflexive
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adherence to the evidence hierarchy, but a recog-
nition of the difficulty interpreting observational
studies of associations between either vitamin D
intake or 25(OH)D and specific health outcomes.
Such associations are highly prone to confounding
by general health and physical activity (i.e., vitamin
D status tends to be higher in healthier individuals
who, for example, have less adiposity, spend more
time outdoors, and have more diverse diets), and
the pitfalls of relying on observational studies to
draw conclusions about the benefits of micronutri-
ent supplements have been widely recognized.224
Conclusions
Vitamin D status is influenced by multiple factors,
including dietary intake, UVB exposure, age, and
race/ethnicity. Factors that increase the risk of
vitamin D deficiency are prevalent worldwide, and
it is likely that many countries have subpopulations
at risk of adverse outcomes owing to low vitamin D
status, including suboptimal bone health and other
negative health outcomes. While nationally repre-
sentative data on vitamin D deficiency are limited,
the majority of studies in both high- and low-
income countries indicate that vitamin D intakes
and status are inadequate on the basis of the recom-
mended guidelines. Given the growing understand-
ing of the established links between vitaminD status
and the incidence of respiratory infections and
asthma, as well as emerging research on the poten-
tial effects of vitaminD status on selected pregnancy
and newborn outcomes, it is important to encour-
age further research to address the most critical
gaps in knowledge regarding thismicronutrient and
to generate accurate information about the global
prevalence of vitamin D deficiency. It is necessary to
explore a diverse range of food fortification vehicles
appropriate in different sociocultural and geo-
graphic contexts and to investigate options for safe
and effective supplementation programs to address
vitamin D deficiency in vulnerable populations
worldwide.
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